L-R: Michael Arciero, general counsel and head of IP, and John Milad, CEO at ERS Genomics

27 February 2025NewsEuropeMarisa Woutersen

‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off

The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the portfolio’s future, finds Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

CRISPR patents revoked following Nobel Prize winners’ withdrawal

12 November 2024 The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows unfavourable preliminary opinion from the EPO | Cancelled patents not expected to impact ongoing licensing agreements for CRISPR technology, says licensor.

Europe

‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

27 September 2024 A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off

More on this story

Editor's picks

Editor's picks

More features